Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Equity Average (2016 - 2026)

Heron Therapeutics filings provide 15 years of Equity Average readings, the most recent being $11.7 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 137.79% to $11.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.7 million, a 137.79% increase, with the full-year FY2025 number at -$9.7 million, up 71.43% from a year prior.
  • Equity Average hit $11.7 million in Q1 2026 for Heron Therapeutics, down from $14.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $50.8 million in Q1 2022 to a low of -$39.0 million in Q3 2024.
  • Median Equity Average over the past 5 years was -$25.4 million (2023), compared with a mean of -$11.9 million.
  • Biggest five-year swings in Equity Average: tumbled 9493.56% in 2023 and later soared 139.67% in 2025.
  • Heron Therapeutics' Equity Average stood at $18.0 million in 2022, then tumbled by 271.45% to -$30.9 million in 2023, then dropped by 19.26% to -$36.8 million in 2024, then soared by 139.67% to $14.6 million in 2025, then dropped by 19.67% to $11.7 million in 2026.
  • The last three reported values for Equity Average were $11.7 million (Q1 2026), $14.6 million (Q4 2025), and -$6.2 million (Q3 2025) per Business Quant data.